← Issue №17/ week of Oct 25, 2026/ the whole section, in full

Colorectal, in full.

All 4 Colorectal papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 4, in full

most clinically useful first · the 1 the issue led with is ruled in green
Colorectal rct · n=400 · Oct 24, 2026 · Lancet · IF 98.4

14-day versus 28-day trifluridine-tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan.

New evidencecolorectal cancer
Clinical takeawayConsider the 14-day trifluridine-tipiracil plus bevacizumab schedule for refractory metastatic colorectal cancer to reduce toxicity, including neutropenia, while maintaining survival outcomes compared to the 28-day schedule.
What it foundThe 14-day trifluridine-tipiracil plus bevacizumab schedule showed non-inferior overall survival (HR 0.93, 95% CI 0.80-1.08) compared to the 28-day schedule, with median survival of 11.3 vs 10.3 months.
ContextThis confirms the 14-day schedule as a viable alternative to the conventional 28-day regimen, addressing toxicity concerns without compromising survival.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Sakakida T … PRABITAS investigators · The Lancet · IF 98.4 · PubMed ↗Permalink
Colorectal prospective cohort · n=320 · Oct 20, 2026 · J Gastroenterology · IF 5.7

Risk factors for non-closure of diverting loop ileostomy after rectal cancer surgery: a multicenter prospective study conducted by the Clinical Study Group of Osaka University, Colorectal Group.

New evidencerectal cancercolorectal surgeryepidemiologybiomarker
Clinical takeawayCounsel patients preoperatively about the risk of permanent stoma, particularly if they have ASA-PS ≥2, advanced clinical stage, or low serum albumin (<3.5 g/dL).
What it found6.9% of diverting loop ileostomies were not closed within 1 year; patients with non-closure more often had ASA-PS 2 or higher (86.4% vs 63.8%), stage III-IV disease (68.2% vs 38.9%) and albumin below 3.5 g/dL (31.8% vs 7.4%) than those closed.
ContextConfirms known risk factors for stoma non-closure and provides specific rates for preoperative counseling.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Miyo M … Clinical Study Group of The University of Osaka, Colorectal Group (CSGO-CG) · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
Colorectal rct · n=52 · Oct 23, 2026 · Nature Medicine · IF 52.5

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

New therapybasic sciencetranslationalbiomarker
Clinical takeawayNo clinical action yet: this is a phase 1/2 trial evaluating a novel T cell agonist in ICB-resistant solid tumors. Further phase 2 data are needed before considering clinical use.
What it foundInvikafusp alfa achieved a 14.8% overall objective response rate (4/27) at optimal biological doses (0.08 and 0.12 mg/kg) in ICB-resistant solid tumors, including partial responses in MSS CRC and PD-L1-negative NSCLC.
ContextThis study introduces a first-in-class bispecific T cell agonist targeting Vβ6/Vβ10 subsets, showing preliminary efficacy in ICB-resistant tumors, a population with limited treatment options.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Sullivan RJ … Gulley JL · Nature Medicine · IF 52.5 · PubMed ↗Permalink
Colorectal systematic review · Oct 21, 2026 · J Clin Gastro · IF 2.9

The Burden of Early-Onset Gastric Cancer From 1990 to 2021: A Systematic Analysis for the Global Burden of Disease Study 2021.

Epidemiologyepidemiology
Clinical takeawayNo clinical action yet: this is an epidemiological analysis of global trends and risk factors, not a study of interventions or diagnostics.
What it foundGlobal early-onset gastric cancer age-standardized incidence, death, and DALY rates declined annually by 2.13%, 2.80%, and 2.78% from 1990 to 2021.
ContextConfirms declining trends in early-onset gastric cancer globally but highlights persistent disparities across regions, genders, and socioeconomic indices.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Cui X … Ning S · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
← Back to issue №17 Every section of this issue is one click away, at the top of this page. Follow Colorectal by RSS